875 related articles for article (PubMed ID: 15649852)
21. Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma.
Vatrella A; Ponticiello A; Pelaia G; Parrella R; Cazzola M
Pulm Pharmacol Ther; 2005; 18(2):89-92. PubMed ID: 15649850
[TBL] [Abstract][Full Text] [Related]
22. Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma.
Wiegand L; Mende CN; Zaidel G; Zwillich CW; Petrocella VJ; Yancey SW; Rickard KA
Chest; 1999 Jun; 115(6):1525-32. PubMed ID: 10378544
[TBL] [Abstract][Full Text] [Related]
23. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
[TBL] [Abstract][Full Text] [Related]
24. Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group.
Paggiaro PL; Giannini D; Di Franco A; Testi R
Eur Respir J; 1996 Aug; 9(8):1689-95. PubMed ID: 8866596
[TBL] [Abstract][Full Text] [Related]
25. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance.
Donohue JF; Hanania NA; Sciarappa KA; Goodwin E; Grogan DR; Baumgartner RA; Hanrahan JP
Ther Adv Respir Dis; 2008 Apr; 2(2):37-48. PubMed ID: 19124357
[TBL] [Abstract][Full Text] [Related]
26. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
Baloira Villar A; Vilariño Pombo C
Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis.
Hordvik NL; Sammut PH; Judy CG; Colombo JL
Pediatr Pulmonol; 2002 Oct; 34(4):287-96. PubMed ID: 12205570
[TBL] [Abstract][Full Text] [Related]
28. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
Maesen FP; Smeets JJ; Sledsens TJ; Wald FD; Cornelissen PJ
Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
[TBL] [Abstract][Full Text] [Related]
29. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD).
Boyd G; Morice AH; Pounsford JC; Siebert M; Peslis N; Crawford C
Eur Respir J; 1997 Apr; 10(4):815-21. PubMed ID: 9150318
[TBL] [Abstract][Full Text] [Related]
30. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group.
Boyd G
Eur Respir J; 1995 Sep; 8(9):1494-8. PubMed ID: 8575574
[TBL] [Abstract][Full Text] [Related]
31. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
32. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
Bouros D; Kottakis J; Le Gros V; Overend T; Della Cioppa G; Siafakas N
Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
[TBL] [Abstract][Full Text] [Related]
33. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters.
Terzano C; Petroianni A; Ricci A; Allegra L
Eur Rev Med Pharmacol Sci; 2005; 9(4):209-15. PubMed ID: 16128040
[TBL] [Abstract][Full Text] [Related]
35. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
36. Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol.
Blake K; Pearlman DS; Scott C; Wang Y; Stahl E; Arledge T
Ann Allergy Asthma Immunol; 1999 Feb; 82(2):205-11. PubMed ID: 10071526
[TBL] [Abstract][Full Text] [Related]
37. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease.
Ryan S; Doherty LS; Rock C; Nolan GM; McNicholas WT
Respiration; 2010; 79(6):475-81. PubMed ID: 19684384
[TBL] [Abstract][Full Text] [Related]
38. The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma.
Dal Negro RW; Micheletto C; Tognella S; Trevisan F; Guerriero M
Eur Ann Allergy Clin Immunol; 2006 May; 38(5):153-7. PubMed ID: 17058847
[TBL] [Abstract][Full Text] [Related]
39. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Calverley P; Pauwels R; Vestbo J; Jones P; Pride N; Gulsvik A; Anderson J; Maden C;
Lancet; 2003 Feb; 361(9356):449-56. PubMed ID: 12583942
[TBL] [Abstract][Full Text] [Related]
40. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.
Bateman ED; Kornmann O; Schmidt P; Pivovarova A; Engel M; Fabbri LM
J Allergy Clin Immunol; 2011 Aug; 128(2):315-22. PubMed ID: 21807250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
